“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Portola

Protocol Number
Portola Pharmaceuticals 13-601

To Learn More Call
201-510-0910

A Multicenter Open-Label, Randomized Phase 1b/2, Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Lenalidomide, with and without Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Pharmacyclics

Protocol Number
Pharmacyclics PCYC-1123-CA

To Learn More Call
201-510-0910

Randomized Phase III Trial of Haploidentical HCT with or without an Add back Strategy of HSV-Tk Donor Lymphocytes in Patients with High Risk Acute Leukemia

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
MolMed

Protocol Number
TK008

To Learn More Call
201-510-0910

Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Type of Cancer
Lung

Site
Hackensack

Sponsor
Mirati

Protocol Number
265-109

To Learn More Call
201-510-0910

“Phase I study of single-agent and combined checkpoint inhibition after allogeneic hematopoietic stem cell transplantation in patients at high risk for post-transplant recurrence

Sponsor
Hackensack UMC

Protocol Number
Hackensack UMC CPIT Trial 002

To Learn More Call
201-510-0910

OPTIMIzE seeks to understand evolving patterns of care and estimate overall survival rates in patients with unresectable or metastatic Melanoma in the clinical practice setting

Sponsor
Bristol=Myers Squibb

Protocol Number
Nristol Myers Squibb CA209-357 OPTIMIZE

To Learn More Call
201-510-0910

An Open-Label Multicenter Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Subjects With Advanced Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma

Sponsor
Eisai

Protocol Number
H3B-6527-G000-101

To Learn More Call
201-510-0910

A Phase 2/3 Trial combining nivolumab, Elotuzmab, Pomalidomide, and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Sponsor
Bristol-Myers Squibb

Protocol Number
Bristol-Myers Squibb CA209-602

To Learn More Call
201-510-0910

Prospective Multicenter International Observational Study for Determination of a Cutaneous Lymphoma International Prognostic Index Model and Impact of Major Therapies in Patients with Advanced Mycosis Fungoides and Sézary Syndrome Advanced Stage PROCLIPI Project by the Cutaneous Lymphoma International Consortium (CLIC) Collaborative Alliance

Type of Cancer
Lymphoma

Site
Hackensack

Sponsor
Stanford University

Protocol Number
Stanford University PROCLIP

To Learn More Call
201-510-0910

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B-Cell of T-Cell Non Hodgkin Lymphoma (NHL)

Type of Cancer
Lymphoma

Site